Rajkot-based Anlon Healthcare, a manufacturer of active pharmaceutical ingredients (APIs), intermediates, and formulations, has announced a price band of ₹86–91 per share for its upcoming initial public offering (IPO).
The IPO will open on August 26 and close on August 29, with the anchor book scheduled for August 25. The basis of allotment will be finalized on September 1, followed by refunds and share credits on September 2. The company is set to debut on the stock exchanges on September 3.
The issue comprises a fresh offer of 1.33 crore shares, amounting to about ₹121 crore at the upper price band. Proceeds will be used for manufacturing facility expansion (₹30.7 crore), working capital needs (₹43.15 crore), debt repayment, and general corporate purposes.
Interactive Financial Services is the sole book-running lead manager for the IPO.
Anlon Healthcare, which counts Kronox Lab Sciences, AMI Organics, and Supriya Lifescience as peers, reported a profit of ₹9.65 crore in FY24, up from ₹5.82 crore a year earlier, though revenue fell to ₹66.6 crore from ₹112.9 crore. For the 10 months ended January 2025, profit stood at ₹12 crore on revenue of ₹77.2 crore.
